Microbot Medical Expands Sales Footprint and Highlights User Satisfaction

HINGHAM, Mass., Sept. 25, 2026 /CourierPR/ -- Microbot Medical Inc., a commercial-stage medical device company, announced its continued growth strategy during an analyst meeting held in New York City on Thursday, September 24, 2026. The company highlighted the progress of its commercial expansion and user satisfaction with its LIBERTY System, a single-use, remotely operated robotic system for peripheral endovascular procedures.

According to the company, it is on track to have 12 sales territories by the end of the year, marking an expansion into Western U.S. with its first customer in California and its existing presence in North Carolina. This move is part of the company's broader strategy to engage with Value Analysis Committee (VAC) processes earlier, aiming to accelerate the adoption of the LIBERTY System across multiple hospital systems.

To support this strategy, Microbot Medical has hired three additional Area Sales Managers and an additional Regional Sales Director, focusing on new sales territories. The company is also advancing its operating efficiencies, including the addition of a second manufacturing line and the adoption of more efficient manufacturing processes. These changes are expected to result in positive gross margins in 2027.

The LIBERTY System, the only FDA-cleared, single-use, remotely operated robotic solution for precision, efficiency, and safety in endovascular procedures, has been designed to reduce radiation exposure and physical strain. The company's commitment to innovation and its strong intellectual property portfolio are driving the future of endovascular care.

Microbot Medical Inc. continues to explore potential expansions to certain international markets, including Asia and the Middle East, where it can leverage its FDA clearance. The company is also engaged with regulatory bodies to support future CE mark approval, which is expected in late Q4 2026 or early Q1 2027.

The company's forward-looking statements, including those related to future financial and operating results, future adoption of products, and future growth, are subject to risks and uncertainties. These include market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and the development of future versions of or applications for the system. The company also faces uncertainties related to regulatory pathways and approvals, as well as political, social, and geopolitical conditions.